This narrative review explores the cardiovascular effects of marine omega-3 fatty acids, focusing on eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Clinical evidence, particularly from the REDUCE-IT trial, demonstrates that high-dose EPA (4 g/day of icosapent ethyl) can significantly reduce major adverse cardiovascular events (MACE) by 25% in high-risk individuals.
